Quantum-Si Q2 2022 Earnings Report
Key Takeaways
Quantum-Si reported a net loss of $32.4 million and an adjusted EBITDA of negative $25.8 million for the second quarter of 2022. The company held $400.7 million in cash and cash equivalents and investments in marketable securities as of June 30, 2022.
Demonstrated recognition of 15 out of 20 amino acids, representing a path to more than 70% coverage of the human proteome.
Released an application note demonstrating the use of Quantum-Si’s PlatinumTM sequencing instrument to directly sequence arginine post-translational modifications.
Executing well on supply chain initiatives, including the build-up of PlatinumTM instrument inventory and scale-up of semiconductor chip and reagent kit production.
Increased efforts to manage costs and improve efficiencies, expecting operating expenses to grow 40-50% year-over-year in 2022, down from a prior expectation of 70-80%.
Quantum-Si
Quantum-Si
Forward Guidance
The company expects operating expenses to grow 40-50% year-over-year in 2022.